ClinicalTrials.gg
Active, not recruitingNCT03682068NILEUpdated Aug 20, 2026

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

A Phase 3 interventional study of Durvalumab and Tremelimumab in Unresectable Locally Advanced Urothelial Cancer and Metastatic Urothelial Cancer, sponsored by AstraZeneca. Active, not recruiting at 222 sites in 22 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,246
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.

Enrollment
Largest of 19
1,246 · median 39
Started
2018
with 4 others
Phase 3
3 of 19
none open now
Primary completion
2026-06
later than 3 of 11 live
Registered
6th of 19
by date
Lead sponsor
5 of 19
AstraZeneca

Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one has the largest enrollment, is one of 5 that started in 2018, is one of 3 in phase 3, reaches primary completion later than 3 of the 11 other live ones, and was the 6th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing durvalumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).

03

Conditions studied

  • Unresectable Locally Advanced Urothelial Cancer
  • Metastatic Urothelial Cancer

Keywords

  • renal pelvis
  • ureters
  • urinary bladder
  • urethra
  • bladder cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with or cytologically documented, unresectable, locally advanced or transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)
  • Patients who have not been previously treated with chemotherapy. Patients who have received prior definitive chemoradiation, or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].
  • At least 1 lesion, not previously irradiated, that qualifies as a 1.1 target lesion at baseline.
  • World Health Organization (WHO)/ (ECOG) performance status (PS) of 0 or 1 at enrolment
  • Adequate organ and marrow function as defined in the protocol
  • ≥12 weeks in the opinion of the investigator
  • Evidence of status, or negative urinary or serum pregnancy test for female pre-menopausal patients.

Key Exclusion Criteria:

  • Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin), including but not limited to, other , anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies, except therapeutic anticancer vaccines, which are permitted. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.
  • No severe concomitant condition that requires medication
  • Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Patients who may be eligible for or are being considered for radical resection during the course of the study.
  • Any medical to platinum (cisplatin or carboplatin) based doublet chemotherapy and/or known allergy or to any of the study drugs or any of the study drug
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,246 participants (actual)

Study arms

  • Experimental
    Durvalumab in Combination with SoC Chemotherapy

    Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks. All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles: * cisplatin+ gemcitabine * If the patient is cisplatin-ineligible, carboplatin + gemcitabine

    Drug: Durvalumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + Gemcitabine

  • Experimental
    Durvalumab in Combination with Tremelimumab+SoC Chemotherapy

    Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks Tremelimumab will be provided for 4 cycles. All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles: * cisplatin+ gemcitabine * If the patient is cisplatin-ineligible, carboplatin + gemcitabine

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + Gemcitabine

  • Active comparator
    SoC Chemotherapy

    Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles: * cisplatin+ gemcitabine * If the patient is cisplatin-ineligible, carboplatin + gemcitabine

    Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + Gemcitabine

Interventions

  • Durvalumab IV (intravenous infusion)

    Also known as: MEDI4736

  • Tremelimumab IV (intravenous infusion)

  • DrugCisplatin + Gemcitabine

    Drug pages: Cisplatin · Gemcitabine

    Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

  • DrugCarboplatin + Gemcitabine

    Drug pages: Carboplatin · Gemcitabine

    Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause

    Time frame: approximately 5 years

Secondary outcomes

  1. Overall Survival (OS)

    Additional analysis beyond the primary endpoint

    Time frame: approximately 5 years

  2. Overall Survival at 24 months (OS24)

    The OS24 will be defined as the Kaplan-Meier estimate of OS at 24 months

    Time frame: 24 months

  3. Progression Free Survival (PFS)

    PFS (per RECIST 1.1) will be defined as the time from the date of randomization until the date of first objective disease progression or death

    Time frame: approximately 5 years

  4. Alive and Progression Free Survival at 12 months (APF12)

    The APF12 will be defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1) at 12 months

    Time frame: 12 months

  5. Objective Response Rate (ORR)

    ORR (per RECIST 1.1) is defined as the number (%) of patients with at least 1 visit response of complete response or partial response and will be based on a subset of all randomized patients

    Time frame: approximately 5 years

  6. Duration of Response (DoR)

    DoR (per RECIST 1.1) will be defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression

    Time frame: approximately 5 years

  7. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects with the best overall response of complete response, partial response or stable disease per RECIST 1.1

    Time frame: approximately 5 years

  8. Time from randomization to second (PFS2)

    PFS2 will be defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the PFS endpoint or death

    Time frame: approximately 5 years

  9. To assess disease-related symptoms, physical functioning, and other Health-related quality of life

    Collection of patient reported outcome questionnaires

    Time frame: approximately 5 years

Other outcomes

  1. To assess safety using a summary of adverse events.

    Adverse Events (both in terms of MedDRA preferred terms and CTCAE grade) will be listed individually by patient. The number of patients experiencing each Adverse Event will be summarized by treatment arm and CTCAE grade

    Time frame: approximately 5 years

  2. To assess pharmacokinetics of Durvalumab and Tremelimumab

    Serum concentrations of Durvalumab and Tremelimumab

    Time frame: approximately 5 years

  3. To assess immunogenicity of Durvalumab and Tremelimumab

    Presence of anti-drug antibodies for Durvalumab and Tremelimumab

    Time frame: approximately 5 years

07

Study locations

222 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Salinas, California 93901, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Truckee, California 96161, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Bozeman, Montana 59715, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1120AAT, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1419AHL, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1426ANZ, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Macquarie University, 2109, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Orange, 2800, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    Curitiba, 80810-050, Brazil
  • Research Site
    Fortaleza, 60336-232, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Ribeirão Preto, 14048-900, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Salvador, 41.950-610, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1797, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G IX6, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Dalian, 116027, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200072, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjin, 300211, China
  • Research Site
    Tianjin, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Ostrava, 708 52, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 140 59, Czechia
  • Research Site
    Prague, 180 81, Czechia
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Budapest, 1145, Hungary

Showing the first 100 of 222 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mamede I, Escalante-Romero L, Celso DSG, Reis PCA, Dacoregio MI, Alves AC, Stecca C. Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Genitourin Cancer. 2024 Oct;22(5):102154. doi: 10.1016/j.clgc.2024.102154. Epub 2024 Jul 11. PubMed 39094286 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jun 2026, 92 months.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 92 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Sep 24, 2018
StartActual
Sep 27, 2018
Primary completionActual
Jun 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03682068
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 24, 2018
Start date
Sep 27, 2018
Primary completion
Jun 1, 2026
Completion
Jun 1, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion